Rüdesheim S, Predicting the effect of drug-gene and drug-drug-gene interactions on the pharmacokinetics of CYP2D6 substrates - leveraging the CYP2D6 activity score system in physiologically based pharmacokinetic modelling, 2024

Müller MA, Die vielfältigen Facetten der Arzneimitteltherapiesicherheit: Mittelbare und unmittelbare Ansatzpunkte zur Verbesserung der Arzneimitteltherapiesicherheit, 2023

Feick D, Impact of drug-gene-disease interactions and diurnal variation on exogenous and endogenous renal transporter substrates: a physiologically based pharmacokinetic modeling approach, 2022

Kovar L, Physiologically based pharmacokinetic modeling providing insights into the pharmacokinetics of buprenorphine, fentanyl and nicotine in adult and pediatric patients, 2022

Van De Vyver A, Quantitative approaches in support of the early development of T-cell redirecting therapies, 2022

Wojtyniak JG, Model informed drug development and precision doing for drug-drug-gene-interactions: applications of physiologically-based pharmacokinetic modeling, 2021

Volz AK, Modelling and simulation techniques to investigate pharmacokinetics, pharmacodynamics, and drug-drug interactions, 2021

Lott D, Quantitative Assessment of the effects of the selective S1P1 receptor modulator ponesimod using pharmacometric modeling and simulation, 2018

Moj D, Translational physiologically-based pharmacokinetic (PBPK) modeling and simulation to support drug development and pharmacotherapy, 2018

Titze M, Novel approaches for translational research in oncology: Pharmacometric modeling of oncolytic virus dynamics and a new Tyrosine Kinase Inhibitor, 2017

Master / Diplom

Neuschwender F, Physiologically based pharmacokinetic modeling of tetrahydrocannabinol and its metabolites in pigs and scaling to healthy humans, 2024

Wojtyniak D, Physiologically-based pharmacokinetic modelling of mirtazapine and its desmethyl metabolite to describe complex drug-interaction-scenarios and potential applications in therapeutic drug monitoring, 2024

Klein MM, Structured data collection of adverse drug reactions in geriatric patients, 2023

Meltzow A, Physiologically-based pharmacokinetic modelling of cisplatin and oxaliplatin, 2023

Loer HLH, Physiologically based pharmacokinetic (PBPK) modeling of clopidogrel for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 drug-drug interaction predictions, 2023

Endres S, Physiologically-based pharmakokinetic modeling of drug-drug-food-gene interactions of phenytoin and its prodrug fosphenytoin, 2021

Mees EM, The value of drug-grapefruit interactions in physiologically based pharmacokinetic modeling, 2021

Josten E, Einfluss von Stationsapotheker*innen auf die Aufgabenverteilung im klinischen Alltag, 2021

Gebert I, Extended drug-disease model for diabetes type 2: effects of weight change and obesity on disease progression, 2021

Weber A, PBPK modeling of dermal absorption, 2021

Imbery P, Einfluss von pharmazeutischer Betreuung durch Stationspharmazeuten auf die Arzneimitteltherapiesicherheit, 2021

Nagel C, Einfluss von Nahrung auf die Arzneimitteltherapiesicherheit, 2021

Roh A, Optimization of package information leaflets – Influence of one-page-summary-sheets (OPSS) on adherence and drug therapy safety, 2021

Rüdesheim S, Physiologically-based pharmacokinetic (PBPK) modeling of the CYP2D6 substrate metoprolol, 2019

vom Hofe L, Physiologically-based pharmacokinetic modeling of warfarin, 2019

Scheer V, Erhebung der Qualität des Entlassmanagements in der Inneren Medizin eines vollversorgenden Krankenhauses, 2019

Müller R, Erhebung und Evaluation arzneimittelbezogener Probleme nach hämatopoetischer Stammzelltransplantation, 2019

Marok FZ, Physiologically-based pharmacokinetic modeling of the DPYD substrate 5-fluorouracil and its prodrug capecitabine, 2019

Fuhr LM, Effective removal of dabigatran by idarucizumab - a physiologically-based pharmacokinetic modeling approach, 2019

Hassan F, Whole-body physiologically-based pharmacokinetic (PBPK) modeling of CYP3A4 inhibitors: Verapamil and its metabolite norverapamil, 2018

Szafarczyk N, Medikationsanalyse bei hämatopoetischer Stammzelltransplantation, 2018

Opitz R, Der Bundeseinheitliche Medikationsplan in der Praxis - Statusanalyse anhand von stationär aufgenommenen Patienten im Klinikum Saarbrücken, 2018

Türk D, Physiologically-based pharmacokinetic modeling of the CYP2C8 substrate pioglitazone, 2017

Miller R, A population pharmacokinetic model of cortisol stress response, 2017

Wojtyniak JG, A mathematical semi-mechanistic cancer cell cycle model to predict effects of combination therapy and different dosing schedules on cell cycle, tumor growth and therapy outcome, 2016

Fickinger S, A physiologically-based pharmacokinetic model of the strong CYP2C8 inhibitor gemfibrozil, 2016

Dings C, Pharmacokinetic and pharmacodynamic modeling of acetylsalicylic acid and its major metabolites, 2016

Britz H, Physiologically-based pharmacokinetic (PBPK) modeling of dronedarone, 2016

Samajauskaitė R, Impact of chronopharmacology on the pharmacokinetics-pharmacodynamics of propranolol - a mathematical approach, 2015

Maurer LM, Population pharmacokinetic modeling of MDMA (methylendioxymetamphetamine) and its metabolites MDA and HMMA in Ecstasy users, 2014

Dietel K, Investigation of influencing factors on the pharmacokinetic and pharmacodynamic of mirtazapine, 2014